Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings (MEDP) is a leading global clinical research organization accelerating drug development through full-service trial management. This page provides investors and industry professionals with timely updates on MEDP's clinical trial milestones, regulatory developments, and strategic partnerships.
Access official press releases and curated analysis covering key operational areas including therapeutic research advancements, bioanalytical innovations, and global trial management. Our repository ensures transparent tracking of MEDP's progress in oncology, cardiology, and rare disease research sectors.
Discover updates across critical categories: quarterly financial results, FDA submission announcements, international trial initiations, and executive leadership changes. All content is verified through primary sources to maintain accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined monitoring of MEDP's role in advancing clinical research. For real-time updates, consider enabling notifications or subscribing to our institutional research alerts.
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its fourth quarter and fiscal year 2022 financial results on February 13, 2023, after market close. A conference call is scheduled for February 14, 2023, at 9:00 a.m. ET to discuss these results. Participants can register in advance through the provided link. The call will also be accessible via webcast on Medpace's investor website, with a replay available after the event. Medpace is a global clinical contract research organization offering comprehensive services across various therapeutic areas.
Medpace Holdings, Inc. (NASDAQ: MEDP) reported third-quarter 2022 revenue of $383.7 million, up 29.8% year-over-year. Net new business awards reached $470.9 million, yielding a net book-to-bill ratio of 1.23x. GAAP net income was $66.0 million or $2.05 per diluted share, compared to $48.6 million or $1.29 in Q3 2021, with a net income margin of 17.2%. EBITDA increased 48.5% to $89.3 million. The outlook for 2022 anticipates revenue of $1.440 billion to $1.460 billion.
Medpace Holdings, Inc. (Nasdaq: MEDP) will release its third quarter 2022 financial results after market close on October 24, 2022. A conference call will follow on October 25, 2022, at 9:00 a.m. ET to discuss these results. Interested parties can register here. A supplemental slide presentation will be available in the 'Investors' section of their website.
Medpace Holdings, Inc. (MEDP) reported a revenue of $351.2 million for Q2 2022, a 26.2% increase from $278.3 million a year earlier. Net new business awards rose by 16.3% to $450.6 million, achieving a net book-to-bill ratio of 1.28x. The company posted a GAAP net income of $49.4 million, or $1.46 per diluted share, marking a significant increase from the $39.9 million in Q2 2021. EBITDA climbed 42.0% to $68.1 million, equating to a margin of 19.4%. Medpace forecasts 2022 revenue between $1.405 billion and $1.435 billion.
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its Q2 2022 financial results on July 25, 2022, after market close. A conference call is scheduled for July 26, 2022, at 9:00 a.m. ET to discuss the results. Interested participants can register via a provided link or join through the investors section of the Medpace website. A supplemental slide presentation will also be made available ahead of the call. Medpace is a full-service clinical contract research organization focusing on biotechnology, pharmaceuticals, and medical devices.
Medpace Holdings reported a 27.3% increase in revenue for Q1 2022, reaching $330.9 million, up from $260.0 million in Q1 2021. The company achieved net new business awards of $423.0 million, resulting in a net book-to-bill ratio of 1.28x. GAAP net income rose to $61.3 million ($1.69 per diluted share), compared to $43.3 million ($1.14 per diluted share) last year. EBITDA increased by 31.3% to $70.4 million, with a margin of 21.3%. The firm forecasts 2022 revenue between $1.400 billion and $1.460 billion.
Medpace (MEDP), a clinical research organization, has partnered with Matthew 25: Ministries to support humanitarian efforts in Ukraine. The organization donated over
Medpace Holdings, Inc. (NASDAQ: MEDP) will release its first quarter 2022 financial results on April 25, 2022, after market close. A conference call is scheduled for April 26, 2022, at 9:00 a.m. ET to discuss the results. Interested participants can join by dialing 800-219-7113 (domestic) or 574-990-1030 (international) with passcode 3191816, or access the call via webcast on Medpace’s website. The call will be available for replay until May 3, 2022.
Medpace Holdings, Inc. (MEDP) reported a revenue increase of 18.8% to $308.6 million for Q4 2021, compared to $259.7 million in Q4 2020. For the full year 2021, revenue rose 23.4% to $1,142.4 million. The company secured $458.7 million in net new business awards for Q4 2021, up 27.9%, leading to a book-to-bill ratio of 1.49x. However, Q4 GAAP net income decreased slightly to $50.0 million from $50.9 million in the previous year. Full-year net income was $181.8 million. Medpace forecasts 2022 revenue between $1.400 billion and $1.460 billion.
Medpace Holdings, Inc. (Nasdaq: MEDP) will release its fourth quarter and fiscal year 2021 financial results after market close on February 14, 2022. A conference call is scheduled for February 15, 2022, at 9:00 a.m. ET to discuss the results. Interested parties can participate by dialing 800-219-7113 (domestic) or 574-990-1030 (international) using passcode 9164466. The call will be accessible via webcast on the company's website, with a replay available until February 22, 2022.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
